Document is current
Any future updates will be listed below
-
Authors
Bayoumy, Karim
Gaber, Mohammed
Elshafeey, Abdallah https://orcid.org/0000-0001-7128-2701
Mhaimeed, Omar
Dineen, Elizabeth H. https://orcid.org/0000-0002-4704-4495
Marvel, Francoise A.
Martin, Seth S.
Muse, Evan D.
Turakhia, Mintu P.
Tarakji, Khaldoun G.
Elshazly, Mohamed B. https://orcid.org/0000-0002-5802-692X
- License Information
-
More Information
Article History
Accepted: 1 February 2021
First Online: 4 March 2021
Competing interests
: F.A.M. and S.S.M. are co-founders of and hold equity in Corrie Health. Under a licence agreement between Corrie Health and the Johns Hopkins University, the University owns equity in Corrie Health, and the University, F.A.M. and S.S.M. are entitled to royalty distributions related to technology described in the study discussed in this publication. This arrangement has been reviewed and approved by the Johns Hopkins University in accordance with its conflict of interest policies. S.S.M. has received consulting and advisory fees from 89bio, Akcea, Amgen, Astra Zeneca, Esperion, Kaneka, Novo Nordisk, Quest Diagnostics, Sanofi, Regeneron and REGENXBIO and funding from Amgen. M.P.T. has received funding from Apple, AstraZeneca and Boehringer Ingelheim, consulting fees from Abbott, Biotronik, Cardiva Medical, Johnson and Johnson, Medtronic and Novartis, and is an editor for <i>JAMA Cardiology</i>. K.G.T. reports advisory board and consulting roles in AliveCor, Janssen Pharmaceutical, and Medtronic. M.B.E. is a co-founder and holds equity in EMBER Medical, a telemedicine company. The other authors declare no competing interests.
